News archive
News Archive Navigation
icon
News Archive Navigation Language
Showing 650 results
May 2019
-
Media Release
Five nonprofit organizations to receive up to $250,000 through Novartis STEP Program™ to support sickle cell patient initiatives
-
Media Release
Novartis issues voluntary nationwide recall of Promacta® 12.5 mg for oral suspension due to potential peanut contamination
- Voluntary recall of three lots issued after discovering potential cross contamination at a third-party manufacturer- Patients taking Promacta 12.5 mg for oral suspension should contact 1-866-918-… -
Media Release
Novartis issues voluntary nationwide recall of Promacta® 12.5 mg for oral suspension due to potential peanut contamination
-
Media Release
New AveXis data at AAN showed long-term durability of Zolgensma® in patients with spinal muscular atrophy (SMA) Type 1
- Interim long-term follow-up data showed all enrolled Cohort 2 patients maintained motor function and milestones achieved during the Phase 1 START trial- Mean age of follow-up since dosing with… -
Media Release
New AveXis data at AAN showed long-term durability of Zolgensma® in patients with spinal muscular atrophy (SMA) Type 1
-
Media Release
AveXis presented robust data at AAN demonstrating efficacy of Zolgensma® in broad spectrum of spinal muscular atrophy (SMA) patients
- Interim data reported for the first time from STRONG in SMA Type 2 showed rapid motor function gains and milestone achievements with intrathecal Zolgensma (onasemnogene abeparvovec-xioi; AVXS-101… -
Media Release
AveXis presented robust data at AAN demonstrating efficacy of Zolgensma® in broad spectrum of spinal muscular atrophy (SMA) patients
April 2019
-
Media Release
Novartis announces FDA filing acceptance and Priority Review of brolucizumab (RTH258) for patients with wet AMD
- By 2020, over 1.5 million people in the U.S. are likely to have wet AMD, the leading cause of blindness in industrialized countries- Filing is based on Phase III data from the HAWK and HARRIER… -
Media Release
Novartis announces FDA filing acceptance and Priority Review of brolucizumab (RTH258) for patients with wet AMD
-
Media Release
AveXis expands world-leading gene therapy manufacturing capacity with purchase of advanced biologics therapy manufacturing campus in Longmont, Colorado
- Facility to become the largest of four state-of-the-art sites involved in manufacturing of AveXis gene therapies for pipeline of rare genetic diseases including spinal muscular atrophy- AveXis… -
Media Release
AveXis expands world-leading gene therapy manufacturing capacity with purchase of advanced biologics therapy manufacturing campus in Longmont, Colorado
Pagination
- ‹ Previous page
- 1
- …
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- …
- 55
- › Next page